

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 6

Confirmation Number

9477

Application Number

10/826,058

Filing Date

April 15, 2004

First Named Inventor

Falotico

Group Art Unit

1615

Examiner Name

Casey Hogopian

Attorney Docket Number

CRD5079USNP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		3,929,992		Sehgal et al.	12/30/1975	
		3,959,078		Guire	05/25/1976	
		4,350,160		Kolesov et al.	09/21/1982	
		4,366,819		Kaster	01/04/1983	
		4,368,736		Kaster	01/18/1983	
		4,624,257		Berggren et al.	11/25/1986	
		4,722,906		Guire	02/02/1988	
		4,733,665		Palmaz	03/29/1988	
		4,739,762		Palmaz	04/26/1988	
		4,776,337		Palmaz	10/11/1988	
		4,917,090		Berggren et al.	04/17/1990	
		4,917,091		Berggren et al.	04/17/1990	
		5,229,172	A	Cahalan et al.	07/20/1993	
		5,234,447	A	Kaster, et al.	08/10/1993	
		5,308,641	A	Cahalan et al.	05/03/1994	
		5,350,800	A	Verhoeven et al.	09/27/1994	
		5,415,938	A	Cahalan et al.	05/16/1995	
		5,924,997		Campbell	07/20/1999	
		5,837,313	A	Ding et al.	11/17/1998	
Examiner Signature					Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 6	Confirmation Number	9477
	Application Number	10/826,058
	Filing Date	April 15, 2004
	First Named Inventor	Falotico
		1615
	Examiner Name	Casey Hogopian
	Attorney Docket Number	CRD5079USNP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		6,099,562	A	Ding et al.	08/08/2000	
		6,120,536	A	Nilsen et al.	09/19/2000	
		6,153,252	A	Hossainy et al.	11/28/2000	
		6,245,026		Campbell	06/12/2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		WO	98/33443	A1	AngioGuard, Inc.	08-06-1998		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 3 of 6	Confirmation Number	9477
	Application Number	10/826,058
	Filing Date	April 15, 2004
	First Named Inventor	Falotico
	Group Art Unit	1615
	Examiner Name	Casey Hogopian
	Attorney Docket Number	CRD5079USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		AJROLDI, G. et al., "Fluoroelastomers-dependence of relaxation phenomena on compositions", POLYMER, 30, No. 12, (1989): 2180-2187.	
		BERK, B.C. et al., "Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty", J. Am. Coll. Cardio. Vol. 17, No. 6, pp. 111B-117B, 1991	
		CHANG, M.W. et al., "Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent Kinase Inhibitor, p21 Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty", J. Clin. Invest. Vol. 96, pp. 2260-2268, 1995	
		CLOWES, A.W. et al., "Suppression by heparin of smooth muscle cell proliferation in injured arteries", Nature, Vol. 265, pp. 625-626, 1977	
		CLOWES, A.W. et al., "Kinetics of Cellular Proliferation after Arterial Injury", Laboratory Investigation, Vol. 52, No. 6, pp. 611-616, 1985	
		CLOWES, A.W. et al., "Kinetics of Cellular Proliferation after Arterial Injury IV. Heparin Inhibits Rat Smooth Muscle Mitogenesis and Migration", Circulation Research, Vol. 58, No. 6, pp. 839-845, 1986	
		COLBURN, M.D. et al., "Dose responsive suppression of myointimal hyperplasia by dexamethasone", J. Vasc. Surg. Vol. 15, No. 3, pp. 510-518, 1992	
		CURRIER, J.W. et al., "Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit", Supplement II Circulation Vol. 80, No. 4, II-66, 1989.	
		FARB, A. et al., "Vascular Smooth Muscle Cell Cytotoxicity and Sustained Inhibition of Neointimal Formation by Fibroblast Growth Factor 2-Saporin Fusion Protein", Circ. Res. Vol. 80, No. 4, pp. 542-550, 1997	
		FERNS, G.A. et al., "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF", Science, Vol. 253, pp. 1129-1132, 1991	
		FISCHMAN, D., et al. "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease", The New England Journal of Medicine, Volume 331:496-501 (1994)	
		FUKUYAMA J., et al., "Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet", European Journal of Pharmacology 318, pp. 327-332, 1996	
		GUYTON, J.R. et al., "Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin", Circulation Research, Vol. 46, No. 5, pp. 625-634, 1980	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 6

Confirmation Number	9477
Application Number	10/826,058
Filing Date	April 15, 2004
First Named Inventor	Falotico
Group Art Unit	1615
Examiner Name	Casey Hogopian
Attorney Docket Number	CRD5079USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
	HANSON, S.R. et al., "Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone"; Proc. Natl. Acad. Sci. USA (5/1988) 85: 3184-3188.
	HANSSON, G.K., et al., "Interferon- γ Inhibits Arterial Stenosis After Injury" Circulation, Vol. 84, No. 3, pp. 1266-1272, 1991
	JONASSON, L. et al., "Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury", Proc. Natl. Acad. Sci. USA Vol. 85, pp. 2303-2306, 1988
	LIU, M.W. et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit", Circ. Vol. 81, No. 3, pp. 1089-1093, 1990
	LUNDERGAN, C.F. et al., "Peptide Inhibition of Myointimal Proliferation by Angiopeptin, a Somatostatin Analogue", JACC Vol. 17(Supp. B), No. 6. pp. 132B-136B, 1991
	MAJESKY, M.W. et al., "Heparin Regulates Smooth Muscle S Phase Entry in the Injured Rat Carotid Artery", Circ. Res. Vol. 61, No. 2, pp. 296-300, 1987
	MARX, S.O., et al., "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells", Circ. Res., Vol. 76, No. 3, pp. 412-417, 1995.
	NEMECEK, G.M. et al., "Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor <i>in Vitro</i> and Neointimal Proliferation <i>in Vivo</i> ", J. Pharmacol. Exp. Thera. Vol. 248, No. 3, pp.1167-1174, 1989
	OKADA, T. et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation, Neurosurgery, Vol. 25, No. 6, pp. 892-898, 1989
	POWELL, J.S. et al., "Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury", Science, Vol 245, pp. 186-188, 1989
	SERRUYS, P., et al. "A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease", New England Journal of Medicine, Volume 331:489-495 (1994)
	SIMONS, M. et al., "Antisense c-myc oligonucleotides inhibit intimal arterial smooth muscle cell accumulation <i>in vivo</i> ", Nature, Vol. 359, pp. 67-70, 1992
	SNOW, A.D. et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells", Vol. 137, No. 2, pp. 313-330, 1990
	SOLLOT, S.J. et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat", J. Clinical Investigation, Inc. Vol. 95, pp. 1869-1876, 1995

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 6

Confirmation Number	9477
Application Number	10/826,058
Filing Date	April 15, 2004
First Named Inventor	Falotico
Group Art Unit	1615
Examiner Name	Casey Hogopian
Attorney Docket Number	CRD5079USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

TARDIF, J-C., et al. "Probucol and Multivitamins in the Prevention of Restenosis After Coronary Angioplasty", New England Journal of Medicine, Volume 337:365-372 (1997)

WEINBERGER, J. et al., "Intracoronary Irradiation: Dose Response for the Prevention of Restenosis in Swine", Int. J. Radiation Onc. Biol. Phys. Vol. 36, No. 4, pp. 767-775, 1996

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.